C4 Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CCCC research report →
Range $7 – $7
Price Chart
About the company
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutic candidates. Its core strategy involves degrading proteins implicated in disease, addressing a range of conditions including cancer, neurodegenerative disorders, and other illnesses.
- CEO
- Andrew J. Hirsch
- IPO
- 2020
- Employees
- 104
- HQ
- Watertown, MA, US
Get TickerSpark's AI analysis on CCCC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $445.59M
- P/E
- -4.03
- Fwd P/E
- 5.48
- PEG
- -0.09
- P/S
- 12.72
- P/B
- 2.13
- EV/EBITDA
- -4.31
- Div Yield
- 0.00%
- Gross Margin
- 94.86%
- Op Margin
- -318.97%
- Net Margin
- -289.44%
- ROE
- -45.45%
- ROIC
- -35.16%
Latest fiscal year · YoY change
- Revenue
- $35.95M+1.0%
- Gross Profit
- $27.97M-21.4%
- Op Income
- $-104,489,000
- Net Income
- $-104,994,000+0.3%
- EPS
- $-1.27+16.4%
- OCF Growth
- -51.5%
- FCF Growth
- -52.0%
- 52W High
- $5.17
- 52W Low
- $1.69
- 50D MA
- $3.92
- 200D MA
- $2.95
- Beta
- 2.95
- RSI (14)
- 55
- Avg Volume
- 3.08M
No earnings-call transcripts are available for CCCC yet.
- Free Float
- 75.7%
- Shares Outstanding
- 110.57M
- Float Shares
- 83.71M
of shares held by institutions
128 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Morgan Stanley | 8.87M | ▼ 205.06K |
| Ra Capital Management, L.P. | 8.00M | 0 |
| Blackrock, Inc. | 7.90M | ▲ 5.85M |
| Lynx1 Capital Management LP | 7.33M | ▲ 327.79K |
| Bain Capital Life Sciences Investors, LLC | 7.17M | 0 |
| Jpmorgan Chase & Co | 4.75M | ▲ 1.52M |
| Vanguard Capital Management LLC | 4.42M | ▲ 555.88K |
| Vanguard Group Inc | 4.38M | ▲ 1.19M |
| Citadel Advisors LLC | 4.19M | ▲ 1.68M |
| Goldman Sachs Group Inc | 3.53M | ▲ 1.14M |
| Wasatch Advisors LP | 3.52M | ▲ 560.88K |
| Two Sigma Investments, LP | 3.47M | ▲ 434.07K |
Held by 104 ETFs
Biggest fund positions in CCCC by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 10, 26 | REYNO LEONARD | other | 15,325 |
| Jul 10, 26 | REYNO LEONARD | other | 7,397 |
| Jul 1, 26 | Anderson Kenneth Carl | other | 2,650 |
| Jul 1, 26 | GROGAN DONNA ROY | other | 3,341 |
| Jun 24, 26 | Hughes Owen | other | 62,000 |
| Jun 24, 26 | Hoerter Steven L. | other | 62,000 |
| Jun 24, 26 | Koppikar Utpal | other | 62,000 |
| Jun 24, 26 | Anderson Kenneth Carl | other | 62,000 |
| Jun 24, 26 | Cooper Ronald Harold Wilfred | other | 62,000 |
| Jun 24, 26 | Bessen Laura | other | 62,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CCCC coverage
Recent articles, reports, and earnings notes.
Vesicor Therapeutics Is Going Public via SPAC — High-Risk Biotech Bet
Vesicor Therapeutics is a development-stage cancer biotech going public via merger with Black Hawk Acquisition Corp (NASDAQ: BKHA). The setup offers a novel p53-focused platform story, but shareholders should watch the low implied valuation, heavy redemption risk, and dilution overhang.
Should You Buy the Wilco 63 Corporation IPO? Here's the Setup
Wilco 63 Corporation (NASDAQ: WLCOU) is expected to list on 2026-06-18, but the price range has not been disclosed yet. The IPO is a SPAC offering 20,000,000 units, with a stated market cap of $200,000,000. The bull case is a thematic bet on AI, robotics, and automation deal flow; the bear case is simple: this is a blank check company with no operating business yet.
Want a deeper read on CCCC?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
zacks.com · Aug 11
Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?
zacks.com · Jul 7
C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know
zacks.com · Jul 3
C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide Transcript
seekingalpha.com · Jun 18
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
zacks.com · Jun 18
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
globenewswire.com · Jun 11
C4 Therapeutics "Buy" On Cemsidomide Advancement And Competitor's Positive Readout
seekingalpha.com · Jun 2
C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com · Jun 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.